SCHEMBL253300

SCHEMBL253300

C[C@@H](O)[C@@H](O)c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.52
ADRB1 P08588 2/20 0.52
AOC3 Q16853 1/20 0.47
HIF1A Q16665 3/20 0.46
CYP2D6 P10635 2/20 0.46
NFKB1 P19838 2/20 0.46
BLM P54132 2/20 0.44
CYP3A4 P08684 2/20 0.42
CYP1A2 P05177 1/20 0.42
PNMT P11086 1/20 0.42
NISCH Q9Y2I1 1/20 0.41
LMNA P02545 3/20 0.41
ALDH1A1 P00352 1/20 0.41
GLA P06280 1/20 0.41
ACP3 P15309 1/20 0.40
CASP1 P29466 1/20 0.40
TSHR P16473 3/20 0.39
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
IDO2 Q6ZQW0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29528401 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253311 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL29528609 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL29528411 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253784 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253301 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL29528599 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253722 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253312 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL253302 1.00 ADRB2 (0.52) ADRB2ADRB1AOC3HIF1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970112-B1 PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2025-03-12 EP disclosed
EP-2968210-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY BIO PHARM SOLUTIONS CO LTD (KR) 2024-09-11 EP disclosed
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease BIO-PHARM SOLUTIONS CO., LTD. (KR) 2024-03-19 US disclosed
EP-4204395-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE Bio-Pharm Solutions Co., Ltd. (KR) 2023-07-05 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2020-01-07 US disclosed
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2020-01-07 US disclosed
EP-2797879-B1 PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN AND NEUROPATHIC PAIN BIO PHARM SOLUTIONS CO LTD (KR) 2018-12-26 EP disclosed
EP-2590936-B1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO PHARM SOLUTIONS CO LTD (KR) 2018-12-12 EP disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-01-03 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 US disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012096458-A2 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-07-19 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005801-A1 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME CPT1B, MYLK, PYGM ADRB2 183/4885ADRB1 133/4885AOC3 3242/4885
US-10525030-B2 Phenyl carbamate compound and a composition for neuroprotection comprising the same CHAT, BAX, CASP3 ADRB2 3595/4885ADRB1 2777/4885AOC3 887/4885
US-11931332-B2 Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease SNCA, MAPT, CHAT ADRB2 2293/4885ADRB1 1173/4885AOC3 811/4885
US-20120184762-A1 PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES CPS1, BCHE, ACHE ADRB2 4106/4885ADRB1 3859/4885AOC3 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.